Should I buy or sell Enliven Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELVN shares. View ELVN analyst ratings or view top-rated stocks .

What is Enliven Therapeutics' stock price target for 2024?

1 brokers have issued 12 month price objectives for Enliven Therapeutics' shares. Their ELVN share price targets range from $34.00 to $34.00. On average, they anticipate the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 92.4% from the stock's current price. View analysts price targets for ELVN or view top-rated stocks among Wall Street analysts .

How have ELVN shares performed in 2024?

Enliven Therapeutics' stock was trading at $13.84 on January 1st, 2024. Since then, ELVN stock has increased by 27.7% and is now trading at $17.67. View the best growth stocks for 2024 here .

When is Enliven Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ELVN earnings forecast .

How were Enliven Therapeutics' earnings last quarter?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) issued its earnings results on Thursday, March, 14th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.09.

How do I buy shares of Enliven Therapeutics?

Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ELVN

Enliven Therapeutics (ELVN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ELVN Stock Alerts

$17.67

+0.37 (+2.14%)

(As of 04/18/2024 ET)

Compare

Today's Range: $16.76
▼
$18.27
50-Day Range: $11.54
▼
$23.82
52-Week Range: $9.80
▼
$26.00

Volume: 211,501 shs
Average Volume: 216,584 shs
Market Capitalization: $827.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.00

Get Enliven Therapeutics alerts:

Enliven Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 92.4% Upside
$34.00 Price Target
Short Interest: Bearish
19.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.31
Based on 25 Articles This Week
Insider Trading: Selling Shares
$13.21 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.16) to ($2.81) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

527th out of 919 stocks

Pharmaceutical Preparations Industry

230th out of 405 stocks

3.5

Analyst's Opinion

Consensus Rating
Enliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Enliven Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
19.82% of the float of Enliven Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Enliven Therapeutics has a short interest ratio ("days to cover") of 28.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Enliven Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Enliven Therapeutics does not currently pay a dividend.
Dividend Growth
Enliven Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELVN.

3.0

News and Social Media Coverage

News Sentiment
Enliven Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 25 news articles for Enliven Therapeutics this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for ELVN on MarketBeat in the last 30 days.
MarketBeat Follows
5 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,213,762.00 in company stock.
Percentage Held by Insiders
45.80% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Enliven Therapeutics are expected to decrease in the coming year, from ($2.16) to ($2.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enliven Therapeutics is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enliven Therapeutics is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enliven Therapeutics has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Enliven Therapeutics Stock (NASDAQ:ELVN)

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

ELVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELVN Stock News Headlines

April 16, 2024 | insidertrades.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares

April 16, 2024 | insidertrades.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $25,387.30 in Stock

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 13, 2024 | insidertrades.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 53,400 Shares of Stock

April 11, 2024 | insidertrades.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 Shares

April 9, 2024 | insidertrades.com

Rahul D. Ballal Sells 3,485 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

April 4, 2024 | insidertrades.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,237 Shares of Stock

March 31, 2024 | insidertrades.com

Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 28, 2024 | insidertrades.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 Shares

April 18, 2024 | americanbankingnews.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $751,200.00 in Stock

April 17, 2024 | msn.com

Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02

April 16, 2024 | investing.com

Enliven Therapeutics CMO sells $501k in company stock

April 16, 2024 | americanbankingnews.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 14,000 Shares of Stock

April 16, 2024 | americanbankingnews.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 17,500 Shares of Stock

April 16, 2024 | americanbankingnews.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 47,709 Shares

April 16, 2024 | americanbankingnews.com

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3.6% Following Insider Selling

April 14, 2024 | americanbankingnews.com

Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume

April 14, 2024 | americanbankingnews.com

Rahul D. Ballal Sells 53,400 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

April 13, 2024 | americanbankingnews.com

Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week High at $26.00

April 12, 2024 | investing.com

Enliven reports promising Phase 1 data for leukemia drug

April 12, 2024 | americanbankingnews.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 4,875 Shares of Stock

April 11, 2024 | markets.businessinsider.com

Strong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market Potential

April 11, 2024 | finance.yahoo.com

Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program

April 11, 2024 | msn.com

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

April 11, 2024 | marketwatch.com

Enliven Therapeutics Shares Hit 52-Week High After Positive Proof of Concept Data for Blood Cancer Drug

April 11, 2024 | proactiveinvestors.com

Enliven Therapeutics shares rise on promising preliminary data for blood cancer drug

See More Headlines

Receive ELVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ELVN
CUSIP: N/A
CIK: 1672619
Web: imaratx.com
Phone: 617-927-9989
Fax: N/A
Employees: 46
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.00
High Stock Price Target: $34.00
Low Stock Price Target: $34.00
Potential Upside/Downside: +92.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.56%
Return on Assets: -25.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.28
Quick Ratio: 10.28

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.97 per share
Price / Book: 2.96

Miscellaneous

Outstanding Shares: 46,810,000
Free Float: 22,330,000
Market Cap: $827.13 million
Optionable: Optionable
Beta: 1.06

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Samuel S. Kintz M.B.A. (Age 38)
Co-Founder, CEO, Secretary & Director
Comp: $597k
Mr. Benjamin Hohl (Age 35)
CFO & Head of Corporate Development
Comp: $488.5k
Dr. Helen Louise Collins M.D. (Age 61)
Chief Medical Officer
Comp: $558k
Dr. Joseph P. Lyssikatos Ph.D. (Age 59)
Co-Founder, Chief Scientific Officer & Directors
Mr. Anish Patel Pharm.D. (Age 44)
Co-Founder & COO
Dr. Galya D. Blachman Esq. (Age 47)
Ph.D., Chief Legal Officer & Head of Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ELVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enliven Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELVN shares.
View ELVN analyst ratings or view top-rated stocks.
What is Enliven Therapeutics' stock price target for 2024?: 1 brokers have issued 12 month price objectives for Enliven Therapeutics' shares. Their ELVN share price targets range from $34.00 to $34.00. On average, they anticipate the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 92.4% from the stock's current price.
View analysts price targets for ELVN or view top-rated stocks among Wall Street analysts.
How have ELVN shares performed in 2024?: Enliven Therapeutics' stock was trading at $13.84 on January 1st, 2024. Since then, ELVN stock has increased by 27.7% and is now trading at $17.67.
View the best growth stocks for 2024 here.
When is Enliven Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ELVN earnings forecast.

How were Enliven Therapeutics' earnings last quarter?: Enliven Therapeutics, Inc. (NASDAQ:ELVN) issued its earnings results on Thursday, March, 14th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.09.
How do I buy shares of Enliven Therapeutics?: Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELVN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Enliven Therapeutics (ELVN) Stock Price, News & Analysis

Enliven Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Enliven Therapeutics Stock (NASDAQ:ELVN)

ELVN Stock Price History

ELVN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ELVN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™